{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009673","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.970602+00:00","generated_at":"2026-05-27T02:38:15.079480+00:00","sec_items":["8.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbbVie enters $3.0 billion revolving credit facility maturing in 2030","bullets":["On January 30, 2025, AbbVie entered a $3.0 billion unsecured revolving credit agreement with JPMorgan Chase as agent.","The new facility matures on January 30, 2030, and AbbVie had no borrowings outstanding on the effective date.","AbbVie's existing $5.0 billion revolver maturing in March 2028 remains in effect, bringing total revolving capacity to $8.0 billion.","Borrowings under the facility bear variable interest rates and are subject to customary covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009673","json":"https://secwatch.observer/filing/0001104659-25-009673.json","markdown":"https://secwatch.observer/filing/0001104659-25-009673.md","text":"https://secwatch.observer/filing/0001104659-25-009673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925009673/0001104659-25-009673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925009673/tm255474d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-27T02:38:15.079480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}